Results 181 to 190 of about 22,015 (248)

Comparing the pharmacokinetics of adalimumab originator and biosimilar product in patients with Inflammatory bowel disease or autoimmune disease. [PDF]

Saudi Pharm J
Drweesh H, Alotaibi A, Alqassim HA, Eid MM, Emsaad SA, Saad MO, Higazy AS, Alturaiki A, Almutairi F, Alhussain A, Assiri A, Alkofide H, Alruthia Y, Albassam A, Alsultan A.   +14 more
europepmc   +1 more source

The challenges and opportunities for equitable global access to medications for paediatric rheumatology in low-to middle-income countries: a review on behalf of the Paediatric Global Task Force for Musculoskeletal Health. [PDF]

Arthritis Res Ther
Scott C, Slamang W, Dushnicky M, Hause E, Faleye A, Furia F, Cuevas OA, Hadef D, Munro J, Nzabonimpa C, Foster H, Migowa A, Paediatric Global Task Force for Musculoskeletal Health.   +12 more
europepmc   +1 more source

Knowledge and Attitude of Aseer Region Pharmacists Toward Biosimilar Medicines: A Descriptive Study. [PDF]

Healthcare (Basel)
Alqahtani S, Almanasef M.
europepmc   +1 more source

Comparison of treatment with GP2017 (an adalimumab biosimilar) and reference adalimumab in people with plaque psoriasis: a plain language summary of the ADACCESS trial. [PDF]

Immunotherapy
Betteridge N, Blauvelt A, Edgerton C, Fan J, Guerrieri D, Rose L, Brueckmann I, Wang Q.   +7 more
europepmc   +1 more source

Safety and Effectiveness of Multi-Switch Between Adalimumab Originator and Biosimilars: A Multicenter (SUSTAIN) Study. [PDF]

J Clin Med
Shehab M, Almajdi A, Abdullah I, Alrashed F.   +3 more
europepmc   +1 more source

The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savings. [PDF]

Health Aff Sch
Beinfeld MT, Ghule P, LaMountain F, Wong W, Ko S, Chambers JD.   +5 more
europepmc   +1 more source

Biosimilar [PDF]

, 2020
openaire   +1 more source

Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with a Focus on Cytochrome C). [PDF]

Pharmaceuticals (Basel)
Ponamarev VS.
europepmc   +1 more source

Efficacy, Safety, and Cost-Effectiveness of the Infliximab Biosimilar GP-1111 in Patients with Inflammatory Bowel Disease Who Underwent a Nonmedical Switch: A Prospective Cohort Study. [PDF]

Biologics
Pápista M, Resál T, Bacsur P, Kata D, Farkas B, Bálint A, Fábián A, Bor R, Ivány E, Szepes Z, Farkas K, Juhász Z, Buzás N, Molnár T.   +13 more
europepmc   +1 more source

Endophthalmitis Caused by α-Streptococcal Following Intravitreal Ranibizumab Biosimilar Administration Using a Prefilled Syringe. [PDF]

Cureus
Utsunomiya K, Sakurada Y, Kasai H, Tanaka A, Kashiwagi K.   +4 more
europepmc   +1 more source